Search results
Results from the WOW.Com Content Network
In one review of 109 individuals with MFS: overall survival for the entire group was 80% at 3 years and 76% at 5 years; local recurrence-free survival was 95% at 3 years and 88% at 5 years; median survival following local recurrence was 68 months; distant metastasis-free survival was 78% at 3 and 77% at 5 years; and 18 of 25 patients (72%) died ...
The prognosis of phyllodes tumor is good with an overall 87% 10-year survival rate. [5] After wide-margin surgical excision, 98.7% of benign phyllodes tumors and 80% of borderline were cured. [25] In rare cases where the tumor has metastasized, the prognosis is poor. [5] This most commonly occurs in cases of malignant grade phyllodes tumor. [5]
The epithelioid inflammatory myofibroblastic sarcoma subtype of IMT shows sheets of epithelioid to round cells within a myxoid (i.e. appears blue or purple compared to the normal red appearance of connective tissue when appropriately H&E stained and examined under the microscope), collagenous, or mixed myxoid-collagenous matrix, <5% spindle ...
The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer. The 5-year relative survival rate drops to 22% for women with stage IV breast cancer. [3]
Post-treatment local recurrences and metastases were observed in 15% and 38% of cases; 5- and 10-year overall survival rates were 60% and 48%, respectively; Overall median survival time were 10.1 years; and patients with tumors ≥10 cm in longest diameter had an almost 6-fold higher rate of developing metastases than patients with tumors 4 cm ...
EMC patients have a long-term clinical course with a survival rate of 5 years in 90% of patients, 10 years at 70% and 15 years at 60%. Local recurrences occur in up to 48% of patients. [13] Metastasis occurs in approximately 50% of cases with the most frequent occurrence in the lungs, which is common site of metastasis in all sarcomas.
Low-grade fibromyxoid sarcoma (LGFMS) is a rare type of low-grade sarcoma first described by H. L. Evans in 1987. [1] LGFMS are soft tissue tumors of the mesenchyme-derived connective tissues; on microscopic examination, they are found to be composed of spindle-shaped cells that resemble fibroblasts. [2]
A myxoid tumor is a connective tissue tumor with a "myxoid" background, composed of clear, mucoid substance. [1] Atrial myxoma.